

ESC Declaration of Interests Report

2024 ESC Guidelines for the management of chronic coronary syndromes

The ESC reviews relationships with healthcare industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit a yearly Declaration of Interests (DOI) during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the Guidelines, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at www.escardio.org/DOI.

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Adamo Marianna	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : SPEAKER FEES Abbott Vascular : SPEAKER FEES
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease
Ainslie James	2021	Nothing to be declared
	2022	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Nothing to Declare (tick box will not accept anything)
	2023	Nothing to be declared
Andreotti Felicita	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Antithrombotic agents Bayer Healthcare : Antithrombotic agents Amgen : Lipid lowering Bristol Myers Squibb/Pfizer : Oral anticoagulation
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF) Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Andreotti Felicita	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Astrazeneca : Interventional Cardiology</p>
Banning Adrian Paul	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic Foundation : renal denervation Boston Scientific : stents Abbott Vascular : stents</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Interventional Cardiology Abbott Vascular : Interventional Cardiology Medtronic Foundation : Interventional Cardiology Miracor : Interventional Cardiology</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology Abbott Vascular : Interventional Cardiology Medtronic Foundation : Interventional Cardiology Miracor : Interventional Cardiology</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Budaj Andrzej	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : alirocumab Bristol Myers Squibb/Pfizer : apixaban Novartis : canakinumab, inclisiran GlaxoSmithKline : darapladib, losmapimod Amgen : evolocumab, olpasiran Eisai : lorcaserin Novo Nordisk : oral PCSK9 inhibitor Bayer : rivaroxaban, asundexian Astra Zeneca : ticagrelor, dapagliflozin</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : alirocumab Bristol Myers Squibb/Pfizer : apixaban Novartis : canakinumab, inclisiran GlaxoSmithKline : darapladib, losmapimod Amgen : evolocumab, olpasiran Eisai : lorcaserin Novo Nordisk : oral PCSK9 inhibitor Astra Zeneca : ticagrelor, dapagliflozin</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Budaj Andrzej	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Acute Coronary Syndromes Bristol Myers Squibb/Pfizer : Atrial Fibrillation (AF) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Acute Coronary Syndromes Amgen : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Acute Coronary Syndromes Bristol Myers Squibb/Pfizer : Atrial Fibrillation (AF) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Acute Coronary Syndromes Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Buechel Ronny	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiac Amyloidosis GE Healthcare : Cardiac CT</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : EANM Congress 2021</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. GE Healthcare : Cardiac Computed Tomography (CT) Pfizer : Nuclear Imaging IBA : Nuclear Imaging</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Pfizer : Nuclear Imaging</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Gilead : Cardiac Computed Tomography (CT), Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Chiariello Giovanni Alfonso	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Chieffo Alaide	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Coronary Abbott : coronary physiology Abiomed : High Risk PCI and Cadiogenic Shock Edwards Lifesciences : TAVi</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Chieffo Alaide	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abiomed : Acute Heart Failure Boston Scientific : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biosensors : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure Boston Scientific : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biosensors : Valvular Heart Disease</p>
Christodorescu Ruxandra Maria	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Antithrombotic Therapy Viartis : Dyslipidemia Servier : Heart Failure Boehringer-Ingelheim : Heart Failure Pharmacotherapy Travel and meeting support from healthcare industry, independent of the above activities. Servier : Interventional Cardiology</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Christodorescu Ruxandra Maria	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Zentiva : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Viartis : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Chronic Heart Failure</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Novartis : Chronic Heart Failure Boeringer Ingelheim : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes Servier : Hypertension Berlin Chemie AG : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure</p>
Deaton Christi	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure with preserved ejection fraction</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Deaton Christi	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Evelyn Trust Charity National Institutes of Health Research</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association</p>
Doenst Torsten	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Edwards Lifesciences : Consulting RHEIA trial Dr. Franz Köhler Chemie GmbH : lecture Abbott : Presentations on Epic Valve Prothesis Medtronic : Webinar minimally invasive cardiac surgery</p>
	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Dr. Franz Köhler Chemie GmbH : Cardiovascular Surgery Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease</p>
Jones Hywel Wynne	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>
Kunadian Vijay	<p>2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Anticoagulation Astra Zeneca : COPD and CVD Medtronic : Drug coated balloons lecture Sanofi Aventis : Lecture, women and heart disease</p>
	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Acute Coronary Syndromes Bayer AG : Acute Coronary Syndromes</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Bayer AG : Acute Coronary Syndromes</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kunadian Vijay	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Acute Coronary Syndromes Novo-Nordisk : Acute Coronary Syndromes Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor Heart BMJ</p>
Mehilli Julinda	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : antithrombotic drugs Bayer Vital GmbH : antithrombotic drugs Daiichi Sankyo Europe GmbH : antithrombotic drugs SIS Medical AG : DEB Biotronik : DES</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boston Scientific : TAVI</p> <hr style="border-top: 1px dashed black;"/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo Europe GmbH : Acute Coronary Syndromes Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Pfizer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bayer Vital GmbH : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biotronik : Interventional Cardiology SIS Medical AG : Interventional Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boston Scientific : Institutional research grant, principal investigator</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mehilli Julinda	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo Europe GmbH : Acute Coronary Syndromes Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Pfizer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bayer Vital GmbH : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biotronik : Interventional Cardiology SIS Medical AG : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boston Scientific : Institutional research grant, principal investigator</p>
Milojevic Milan	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sorin Group : Intraoperative Cell Salvage</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Section 1. A: In 2021, I received only one speaker honorarium in total less than one thousand euros.</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Training and Education, Other</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Chair of the Committee for Clinical Practice Guidelines at EACTS</p>
Piek Jan Jacob	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Physiology, haemodynamics and microcirculation</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Philips : Physiology, haemodynamics and microcirculation</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Piek Jan Jacob	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Philips : ILIAS-ANOCA, multicenter study on diagnosis and treatment of coronary vasospasm . , Principal investigator Bayer : Treatment of coronary vasospasm with endotheline-1 antagonist , site investigator</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Philips : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : ILIAS-ANOCA, multicenter study on diagnosis and treatment of coronary vasospasm . , Principal investigator Bayer : Treatment of coronary vasospasm with endotheline-1 antagonist , site investigator</p>
Pugliese Francesca	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Siemens Healthcare : Computed Tomography</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Siemens Healthineers : Diagnostic research, Chief investigator</p>
	2023	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Siemens Healthcare : Cardiac Computed Tomography (CT)</p>
Rossello Francisco Javier	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Rubboli Andrea	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Semb Anne Grete	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : speakers fee</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Semb Anne Grete	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Cardiovascular Disease in Special Populations</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiovascular Disease in Special Populations</p>
Senior Roxy	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. GE Heaealthcare ,UK : Equipment Philips : iE33/Epiq7 Lantheus InMedical Imaging,Boston,USA : Luminity Bracco Pharmaceutical : Sonovue</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Dapagliflozin Amgen : Evolocumab Bayer AG : Rivaroxaban Bracco Pharmaceutical : SonovUE</p>
	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography Bracco Pharmaceutical : Echocardiography Lantheus InMedical Imaging,Boston,USA : Echocardiography GE Heaealthcare ,UK : Echocardiography</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure National Institute for Health ,Maryland USA : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Lantheus Medical Imaging Boston USA : Echocardiography NovoNordisk : Other</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Senior Roxy	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Philips : Echocardiography Lantheus InMedical Imaging,Boston,USA : Echocardiography GE Heaealthcare ,UK : Echocardiography Bracco Pharmaceutical,Milan,Italy : Echocardiography</p>
ten Berg Jurrien M	<p>2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : ACS Boehringer-Ingelheim : ACS Ferrer Internacional : ACS Bayer : AF Pfizer : AF</p> <hr style="border-top: 1px dashed black;"/> <p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Acute Coronary Syndromes Daiichi Sankyo : Acute Coronary Syndromes Ferrer Internacional : Acute Coronary Syndromes CeleCOR : Acute Coronary Syndromes</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
ten Berg Jurrien M	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity ZonMw (Dutch Government) institutional grant</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Coronary Syndromes Daiichi Sankyo : Acute Coronary Syndromes CeleCOR : Acute Coronary Syndromes</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. CeleCOR : Acute Coronary Syndromes</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : WOEST-3 RCT, institutional grant, PI</p>
Van Belle Eric	<p>2021 Nothing to be declared</p> <p>2022 Nothing to be declared</p> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Programme Hospitalier de Recherche Clinique (PHRC) - French Ministry of Health funding</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biotronik : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Edwards Lifesciences : Valvular Heart Disease</p>
Van Craenenbroeck Emeline	<p>2021</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : heart failure Boehringer-Ingelheim : heart failure</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Van Craenenbroeck Emeline	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Chronic Heart Failure BMS : Chronic Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <p>Astra Zeneca : Chronic Heart Failure Pfizer : Chronic Heart Failure</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Fund for Scientific Research Flanders, Stichting tegen Kanker</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure BMS : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</p> <p>Astra Zeneca : Chronic Heart Failure</p>
Vidal-Perez Rafael Carlos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Esteve : Diabetes Novartis : Heart Failure Servier : Heart Failure</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <p>Daiichi Sankyo : Atrial Fibrillation Rovi : Heart failure</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Vidal-Perez Rafael Carlos	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Amgen : Risk Factors and Prevention Servier : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Organon : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Daiichi Sankyo : Atrial Fibrillation (AF) Rovi : Chronic Heart Failure</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Almirall Spain : Risk Factors and Prevention Organon : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF) Rovi : Chronic Heart Failure Novo-Nordisk : Risk Factors and Prevention</p>
Vrints Christiaan J M	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Winther Simon	2021	Nothing to be declared
	2022	Nothing to be declared

2024 ESC Guidelines for the management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Winther Simon	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Clinical Emerging Investigator, Novo Nordisk Foundation</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. GE Healthcare : Cardiac Computed Tomography (CT)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Abdel Aziz Islam Shawky	2022	Nothing to be declared
	2023	Nothing to be declared
Abilova Saamai	2022	Nothing to be declared
	2023	Nothing to be declared
Ahrens Ingo	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Acute Coronary Syndromes Bayer Vital : Atrial Fibrillation (AF), Chronic Heart Failure, Acute Heart Failure Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Risk Factors and Prevention Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Pfizer : Training and Education</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF), Risk Factors and Prevention Boehringer-Ingelheim : Chronic Heart Failure Pfizer : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes Bayer Healthcare : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bristol Myers Squibb : Clinical Skills Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Acuet CardioVascular Care Association /ESC</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Ainla Tiia	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : Atrial Fibrillation (AF) Berlin Chemie AG : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Risk Factors and Prevention</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Berlin Chemie AG : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Risk Factors and Prevention</p>
Allam Bachir	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Angel Kristin	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Aytekin Vedat	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Chiesi Pharma : Acute Coronary Syndromes Travel and meeting support from healthcare industry, independent of the above activities. Servier : European Society of Cardiology</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Chiesi Pharma : Acute Coronary Syndromes Pfizer : Atrial Fibrillation (AF) Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Badariene Jolita	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Berlin Menarini : Hypertension Amgen : Other Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Novartis : Other Krka Pharma : Other</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Berlin Menarini : Hypertension Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Amgen : Risk Factors and Prevention, Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis : Other Krka Pharma : Other</p>
Bani Marjeh Mohammed Yassin	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Becker David	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer Healthcare : Atrial Fibrillation (AF) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Egis Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : History of Cardiology, Chronic Heart Failure</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity National Artificial Intelligence Laboratory</p>
Beleslin Branko	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Krka Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abella Pharm : Rehabilitation and Sports Cardiology</p>
	<p>2023</p> <p>Nothing to be declared</p>
Benamer Hakim	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Interventional Cardiology, Hypertension</p>
	<p>2023</p> <p>Nothing to be declared</p>
Benouna El Ghali Mohamed	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Pharmacology and Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Medtronic : Interventional Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Moroccan society of cardiology board</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Benouna El Ghali Mohamed	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Pharmacology and Pharmacotherapy</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Medtronic : Interventional Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Moroccan society of cardiology board</p>
Bertelli Luca	<p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p>
Boehm Michael	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Chronic Heart Failure, Hypertension Amgen : Chronic Heart Failure, Hypertension Astra Zeneca : Chronic Heart Failure, Hypertension Bayer : Chronic Heart Failure, Hypertension Boehringer-Ingelheim : Chronic Heart Failure, Hypertension Medtronic : Chronic Heart Failure, Hypertension Novartis : Chronic Heart Failure, Hypertension Servier : Chronic Heart Failure, Hypertension Vifor International : Chronic Heart Failure, Hypertension Bristol Myers Squibb : Chronic Heart Failure, Hypertension Cytokinetics : Chronic Heart Failure, Hypertension</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Boehm Michael	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Abbott : Chronic Heart Failure, Hypertension</p> <p>Amgen : Chronic Heart Failure, Hypertension</p> <p>Astra Zeneca : Chronic Heart Failure, Hypertension</p> <p>Bayer : Chronic Heart Failure, Hypertension</p> <p>Boehringer-Ingelheim : Chronic Heart Failure, Hypertension</p> <p>Medtronic : Chronic Heart Failure, Hypertension</p> <p>Novartis : Chronic Heart Failure, Hypertension</p> <p>Servier : Chronic Heart Failure, Hypertension</p> <p>Vifor International : Chronic Heart Failure, Hypertension</p> <p>Bristol Myers Squibb : Chronic Heart Failure, Hypertension</p> <p>Cytokinetics : Chronic Heart Failure, Hypertension</p>
Borger Michael A	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Artivion (formerly CryoLife) : Diseases of the Aorta</p> <p>Abbott : Valvular Heart Disease</p> <p>Edwards Lifesciences : Valvular Heart Disease</p> <p>Medtronic : Valvular Heart Disease</p> <hr/> <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Artivion (formerly CryoLife) : Diseases of the Aorta</p> <p>Abbott : Valvular Heart Disease</p> <p>Edwards Lifesciences : Valvular Heart Disease</p> <p>Medtronic : Valvular Heart Disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Bouraghda Mohamed Abed	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Sanofi Aventis : Acute Coronary Syndromes, Hypertension</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. EPCI international affair comitee</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosensors : Acute Coronary Syndromes Sanofi Aventis : Acute Coronary Syndromes, Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. EPCI international affair comitee</p>
Bryniarski Krzysztof Leszek	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Intravascular coronary imaging in patients after COVID-19, PI</p>
Buccheri Sergio	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Nothing to be declared</p>
Bulatovic Nebojsa	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Capodanno Davide	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Terumo Inc : Interventional Cardiology Chiesi Pharma : Interventional Cardiology Amgen : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Interventional Cardiology</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Terumo Inc : Interventional Cardiology Sanofi Aventis : Interventional Cardiology Sanofi Aventis : Pharmacology and Pharmacotherapy Novo Nordisk : Pharmacology and Pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Interventional Cardiology</p>
Christiansen Evald Hoej	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Vascular : Interventional Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Interventional Cardiology Orbus Neich : Interventional Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Christiansen Evald Hoej	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott Vascular : Interventional Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Philips : Interventional Cardiology Orbus Neich : Interventional Cardiology</p>
De Pauw Michel	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>
Dedic Admir	<p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Dickstein Kenneth	<p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Dingli Philip	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : History of Cardiology, Pharmacology and Pharmacotherapy</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Terumo Inc : Interventional Cardiology</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. MATER DEI HOSPITAL : Consultant cardiologist</p> <p>2023 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Terumo Inc : Interventional Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Dingli Philip	2023 Employment (including part time) in healthcare industry during the year for which you are declaring. MATER DEI HOSPITAL : Consultant cardiologist
Eek Christian	2022 Nothing to be declared
	2023 Nothing to be declared
Elezi Shpend	2022 Nothing to be declared
	2023 Nothing to be declared
Falk Volkmar	2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott : Other Boston Scientific : Other Edwards Lifesciences : Other Medtronic : Other Novartis : Other Biotronik : Other Liva Nova : Other Berlin Heart : Other Cryolife / Jotec : Other Membership or affiliation in political or advocacy groups working in the field of cardiology. Affiliations: -DZHK - ETH – Zurich, Dept. Health Science & Technology, Transl. Cardiovascular Technology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Other Boston Scientific : Other Edwards Lifesciences : Other Medtronic : Other Novartis : Other Biotronik : Other Liva Nova : Other Berlin Heart : Other Cryolife / Artivion : Other</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Affiliations: -DZHK - ETH – Zurich, Dept. Health Science & Technology, Transl. Cardiovascular Technology</p>
Fras Zlatko	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Novartis : HORIZON Trial; VICTORION-2P Trial, site PI; nat coord</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Fras Zlatko	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Slovenian National Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Cardiovascular Disease in Special Populations Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p>
Freixa Pamias Roman	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF), Risk Factors and Prevention Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure, Risk Factors and Prevention Amgen : Pharmacology and Pharmacotherapy</p> <hr/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Daiichi Sankyo : Atrial Fibrillation (AF), Risk Factors and Prevention Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure, Risk Factors and Prevention Amgen : Pharmacology and Pharmacotherapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Gelev Valeri	2022	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Zentiva : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Astra Zeneca : Interventional Cardiology Servier : Interventional Cardiology Boehringer-Ingelheim : Myocardial Disease Novartis : Risk Factors and Prevention</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Biotronik : Interventional Cardiology Actavis : Interventional Cardiology Bracco Pharmaceutical : Interventional Cardiology Servier : Training and Education</p>
Gudmundsdottir Ingibjorg Jona	2022	<p>Travel and meeting support from healthcare industry, independent of the above activities. Abbott : Interventional Cardiology Medtronic : Valvular Heart Disease</p>
	2023	<p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Landspítali participates in the Victorion 2 study, I do not receive any personal salary or have any personal interest., site investigator</p>
Hammami Rania	2022	Nothing to be declared
	2023	Nothing to be declared

2024 ESC Guidelines for the management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure Servier : Hypertension Egis Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Servier : RCT, national coordinator</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Gedeon Richter : Hypertension Egis Pharma : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Servier : RCT, national coordinator</p>
Henriksen Peter	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Merck Sharp & Dohme : Cross-Modality and Multi-Modality Imaging Topics</p>
	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK National Institute for Health and Care Research and British Heart Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Merck Sharp & Dohme : Cross-Modality and Multi-Modality Imaging Topics Vascular Perspectives Ltd : Interventional Cardiology</p>
Holm Anna Cecilia	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Holm Anna Cecilia	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes, Acute Cardiac Care</p>
Huche Lene	<p>2022 Nothing to be declared</p> <p>2023 Nothing to be declared</p>
Hudec Martin	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Acute Coronary Syndromes Medtronic : Interventional Cardiology</p> <p>2023 Nothing to be declared</p>
Ibanez Borja	<p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p>2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Jeger Raban	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>Amgen : Training and Education</p> <p>Astra Zeneca : Training and Education</p> <p>Boston Scientific : Training and Education</p> <p>Daiichi Sankyo : Training and Education</p> <p>Edwards Lifesciences : Training and Education</p> <p>Medtronic : Training and Education</p> <p>Novartis : Training and Education</p> <p>Pfizer : Training and Education</p> <p>Biotronik : Training and Education</p> <p>Terumo Inc : Training and Education</p> <p>GE Healthcare : Training and Education</p> <p>Abbott Vascular : Training and Education</p> <p>Bristol Myers Squibb : Training and Education</p> <p>Cordis : Training and Education</p> <p>Biosense Webster : Training and Education</p> <p>B.Braun : Training and Education</p> <p>Bayer AG : Training and Education</p> <p>Cardionovum : Training and Education</p> <p>MCM Medsys : Training and Education</p> <p>Vascular Medical : Training and Education</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Jeger Raban	<p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Amgen : Training and Education Astra Zeneca : Training and Education Boston Scientific : Training and Education Daiichi Sankyo : Training and Education Medtronic : Training and Education Novartis : Training and Education Pfizer : Training and Education Terumo Inc : Training and Education GE Healthcare : Training and Education Abbott Vascular : Training and Education Bristol Myers Squibb : Training and Education Cordis : Training and Education Biosense Webster : Training and Education B.Braun : Training and Education Bayer AG : Training and Education Cardionovum : Training and Education MCM Medsys : Training and Education Vascular Medical : Training and Education</p>
Karakiriou Maria	<p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p>
Kedev Sasko	<p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Knuuti Juhani	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Siemens Healthcare : Nuclear Imaging GE Healthcare : Nuclear Imaging Bayer : Other Boehringer-Ingelheim : Other Pfizer : Other Merck Sharp & Dohme : Other Lundbeck : Other</p> <hr style="border-top: 1px dashed black;"/> <p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Siemens Healthcare : Nuclear Imaging GE Healthcare : Nuclear Imaging Synektik : Nuclear Imaging Bayer : Other Boehringer-Ingelheim : Other Pfizer : Other Merck Sharp & Dohme : Other</p>
Kober Lars	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kober Lars	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p>
Kovarnik Tomas	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Abbott Vascular : Interventional Cardiology Opsens : Interventional Cardiology</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Boston Scientific : Interventional Cardiology</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology Abbott Vascular : Interventional Cardiology Opsens : Interventional Cardiology</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boston Scientific : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott Vascular : non restricted grant for measurement of intramyocardial resistency, PI</p>
Kusljugic Zumreta	<p>2022</p> <p>Nothing to be declared</p>
	<p>2023</p> <p>Nothing to be declared</p>
Kyriakou Martha	<p>2022</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Chairperson of the nursing working group of Cyprus Society of Cardiology</p>
	<p>2023</p> <p>Nothing to be declared</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Luz Andre	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott Vascular : Interventional Cardiology
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott Vascular : Congenital Heart Disease and Paediatric Cardiology, Stroke
Magavern Emma	2022 Nothing to be declared
	2023 Nothing to be declared
McInerney Angela	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
	2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Training and Education Medtronic : Training and Education Shockwave : Training and Education
Mersa Caius Ovidiu	2022 Membership or affiliation in political or advocacy groups working in the field of cardiology. Romanian Heart Foundation
	2023 Nothing to be declared
Mihaylova Borislava	2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mihaylova Borislava	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>
Mindham Richard	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Mintale Iveta	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Hypertension, Risk Factors and Prevention Berlin Chemie AG : Myocardial Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mintale Iveta	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Servier : Hypertension, Risk Factors and Prevention Berlin Chemie AG : Myocardial Disease Novo-Nordisk : Risk Factors and Prevention</p>
Mitevaska Irena	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Musayev Ogtay	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Nadaraia Kakha	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Acute Coronary Syndromes Berlin Chemie AG : Chronic Heart Failure Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Krka Pharma : Hypertension Novartis : Risk Factors and Prevention Egis Pharma : Risk Factors and Prevention</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Nadaraia Kakha	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Coronary Syndromes Berlin Chemie AG : Chronic Heart Failure Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Gedeon Richter : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Krka Pharma : Hypertension Novartis : Risk Factors and Prevention Egis Pharma : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Chemie AG : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Head of Acute Cardiovascular Care Working group of the Georgian Society of Cardiology</p>
Nesukay Elena	<p>2022 Nothing to be declared</p> <hr/> <p>2023 Nothing to be declared</p>
Neubeck Lis	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Neubeck Lis	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p>
Neumann Franz Josef	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Interventional Cardiology Meril Life : Interventional Cardiology Amgen : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Ferrer Internacional : Pharmacology and Pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Ferrer Internacional : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott Vascular : stent study adjunctive pharmacology, site investigator Boston Scientific : stent study, site investigator Biotronik : stent study, site investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Neumann Franz Josef	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology Amgen : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Ferrer Internacional : Pharmacology and Pharmacotherapy</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Siemens Healthcare : Cardiac Computed Tomography (CT), Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Boston Scientific : Interventional Cardiology Amgen : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Ferrer Internacional : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott Vascular : stent study adjunctive pharmacology, site investigator Boston Scientific : stent study, site investigator Biotronik : stent study, site investigator</p>
Nielsen Jens Cosedis	<p>2022</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p> <hr/> <p>2023</p> <p>Nothing to be declared</p>
Paolisso Pasquale	<p>2022</p> <p>Nothing to be declared</p> <hr/> <p>2023</p> <p>Nothing to be declared</p>
Papafaklis Michail	<p>2022</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Papafaklis Michail	2023	Nothing to be declared
Paradies Valeria	2022	Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Abbott : Research grant to the institution , Principal investigator
	2023	Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Research grant to the institution , Principal investigator
Pasquet Agnes A	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support
Pereira Bruno	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Abbott : Training and Education Travel and meeting support from healthcare industry, independent of the above activities. topmedical : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

2024 ESC Guidelines for the management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Pereira Bruno	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. topmedical : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Piepoli Massimo Francesco	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novo Nordisk : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Menarini, : Chronic Heart Failure</p> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novo Nordisk : Cardiovascular Disease in Special Populations Boehringer Ingelheim : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Menarini, : Chronic Heart Failure</p>
Popescu Bogdan Alexandru	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Other Novartis : Risk Factors and Prevention</p> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UEFISCDI</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Other</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Popescu Bogdan Alexandru	2023	Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief, Romanian Journal of Cardiology (since 2023)
Porela Pekka	2022	Nothing to be declared
	2023	Nothing to be declared
Prescott Eva	2022	Nothing to be declared
	2023	Nothing to be declared
Rakisheva Amina	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
Reinstadler Sebastian	2022	Nothing to be declared
	2023	Nothing to be declared
Revenco Valeriu	2022	Nothing to be declared
	2023	Nothing to be declared
Riccio Carmine	2022	Nothing to be declared
	2023	Nothing to be declared
Richardt Gert	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Deutsche Gesellschaft für Kardiologie (DGK)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Richardt Gert	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology Biotronik : Interventional Cardiology Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Lilly : Pharmacology and Pharmacotherapy</p>
Rocca Bianca	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator</p> <hr/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Ruel Marc	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Cardiovascular Surgery</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Medtronic : Research Grant Support, Minimally Invasive versus STernotomy (MIST) Trial, principal investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Ruel Marc	<p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Associate Editor, Circulation (American Heart Association) Cardiovascular Surgery Content Editor, Circulation (American Heart Association) Canadian Director, Society of Thoracic Surgeons Immediate Past President, Canadian Cardiovascular Society</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Cardiovascular Surgery</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor and Cardiovascular Surgery Content Editor, Circulation (American Heart Association) Canadian Director, Society of Thoracic Surgeons North American Director, International Society for Minimally Invasive Cardiothoracic Surgery</p>
Sandner Sigrid	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Saraste Antti	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Pfizer : Myocardial Disease</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial, site investigator Precordior : Clinical trial, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. European Association of Nuclear Medicine Cardiovascular Committee member</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Scientific advisory board of the Finnish Foundation for Cardiovascular Research member</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Saraste Antti	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Finnish Foundation for Cardiovascular Research Juselius Foundation Research Council of Finland</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) BMS : Echocardiography Pfizer : Myocardial Disease Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Abbott : Valvular Heart Disease</p> <p>Receipt of royalties for intellectual property. Duodecim Publishing Company Ltd : Echocardiography, Cardiac Computed Tomography (CT), Nuclear Imaging, Hybrid and Fusion Imaging, Valvular Heart Disease, Infective Endocarditis</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. NewAmsterdam Pharma : Clinical trial, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. European Association of Nuclear Medicine Cardiovascular Committee member</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Scientific advisory board member of the Finnish Foundation for Cardiovascular Research, Senior editor of Journal of Nuclear Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Shek Aleksandr	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Berlin Menarini : Hypertension Abbott : Other Krka Pharma : Risk Factors and Prevention</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Berlin Menarini : Hypertension Abbott : Other Krka Pharma : Risk Factors and Prevention</p>
Shuka Naltin	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Skoric Bosko	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Berlin Chemie AG : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure Biotest Pharma : Chronic Heart Failure Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Mylan : Hypertension Salveo : Risk Factors and Prevention</p> <hr style="border-top: 1px dashed black;"/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Salveo : Acute Coronary Syndromes Berlin Chemie AG : Atrial Fibrillation (AF) Viartis : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Takeda Pharmaceuticals : Other</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Teva Pharmaceutical Industries : Chronic Heart Failure, Acute Heart Failure, Other Medis Adria : Other</p>
Swanson Neil	<p>2022</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Swanson Neil	2023	Nothing to be declared
Szummer Karolina	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Vifor International : Chronic Heart Failure
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Vifor International : Chronic Heart Failure
Vaartjes Ilonca	2022	Nothing to be declared
	2023	Nothing to be declared
Wijns William	2022	Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member of Rwanda Heart Center, Kigali (Rwanda). Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Senior advisor to Rede Optimus Research and Corrib Core Laboratory, UNiversity of Galway. Co-founder of Argonauts, an innovation facilitator.
	2023	Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity European Commission: Resil-Card Project - We Care Alliance (under EU4Health). European Commission: SmartShape Project (under EU Horizon - Biomaterials section). Membership or affiliation in political or advocacy groups working in the field of cardiology. Board member of Rwanda Heart Center, Kigali (Rwanda). Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Senior advisor to Rede Optimus Research and Corrib Core Laboratory, UNiversity of Galway. Co-founder of Argonauts, an innovation facilitator.
Windecker Stephan	2022	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Medtronic : Valvular Heart Disease Research funding from healthcare industry under your direct/personal responsibility (to department or institution).

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
	<p>Boehringer-Ingelheim : Educational Grant , None Bristol Myers Squibb : Educational Grant , None V-Wave : Sponsored studies (Patient fee) , None Novartis : Sponsored studies (Patient fee), Educational Grant , Principal Investigator Idorsia : Sponsored studies (Patient fee), None CSL Behring : Sponsored studies (Patient fee), Principal investigator Abiomed : Sponsored studies (Patient fee), Principal Investigator Amgen : Educational Grant , None Astra Zeneca : Educational Grant , None Daiichi Sankyo : Educational Grant , None B.Braun : Educational Grant , None Bayer AG : Educational Grant , None Fumedica : Educational Grant , None Cordis Medical : Educational Grant , None Novo Nordisk : Educational Grant, None Pfizer : Funding for IIT, Educational Grant , None Regeneron : Funding for IIT, None Guerbet AG : Funding for IIT, None Boston Scientific : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Biotronik : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Sanofi Aventis : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Johnson & Johnson : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Edwards Lifesciences : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator Medtronic : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator Farapulse Inc : Funding for IIT, Sponsored studies (Patient fee), None Abbott : Funding for IIT, Sponsored studies (Patient fees), Educational Grant , Site investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
	<p>MedAlliance : Sponsored studies (Patient fee), None Inari Medical : Sponsored studies (Patient fee), None Miracor medical : Sponsored studies (Patient fee), None Pharming Tech : Sponsored studies (Patient fee), None</p> <p>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Interventional Cardiology - Deutsches Zentrum für Herzkrankheit, CSG Member and Vice-Speaker Media - JACC CV Interventions, Deputy Editor Up to date, Section Editor</p> <hr/> <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Educational Grant , None Bristol Myers Squibb : Educational Grant , None V-Wave : Sponsored studies (Patient fee) , None Novartis : Sponsored studies (Patient fee), Educational Grant , Principal Investigator Idorsia : Sponsored studies (Patient fee), None CSL Behring : Sponsored studies (Patient fee), Principal investigator Abiomed : Sponsored studies (Patient fee), Principal Investigator Amgen : Educational Grant , None Astra Zeneca : Educational Grant , None Daiichi Sankyo : Educational Grant , None B.Braun : Educational Grant , None Bayer AG : Educational Grant , None</p>

2024 ESC Guidelines for the management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
	<p>Fumedica : Educational Grant , None Cordis Medical : Educational Grant , None Novo Nordisk : Educational Grant, None Pfizer : Funding for IIT, Educational Grant , None Regeneron : Funding for IIT, None Guerbet AG : Funding for IIT, None Boston Scientific : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Biotronik : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Sanofi Aventis : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Johnson & Johnson : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , None Edwards Lifesciences : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator Medtronic : Funding for IIT, Sponsored studies (Patient fee), Educational Grant , Principal Investigator Farapulse Inc : Funding for IIT, Sponsored studies (Patient fee), None Abbott : Funding for IIT, Sponsored studies (Patient fees), Educational Grant , Site investigator MedAlliance : Sponsored studies (Patient fee), None Inari Medical : Sponsored studies (Patient fee), None Miracor medical : Sponsored studies (Patient fee), None Pharming Tech : Sponsored studies (Patient fee), None</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Media - JACC CV Interventions, Deputy Editor Up to date, Section Editor</p>
Witkowski Adam	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Wolak Arik	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Cardiac Computed Tomography (CT)</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Philips : Cardiac Computed Tomography (CT), Cardiac Magnetic Resonance (CMR)</p>
Zdravkovic Marija	<p>2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the National Assembly, Republic of Serbia and member of the City Assembly, City of Belgrade, Serbia. Member of the Presidency of the SNS political party</p>
	<p>2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Galenika : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Siemens Healthcare : Cardiac Magnetic Resonance (CMR)</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the National Assembly, Republic of Serbia. Member of the Presidency of the SNS political party</p>
Zeppenfeld Katja	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Zeppenfeld Katja	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>
Zholdin Bekbolat	<p>2022</p> <p>Nothing to be declared</p> <hr/> <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Krka Pharma : Hypertension</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Arbelo Elena	2021 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial fibrillation
	2022 Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Atrial Fibrillation (AF)
	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Marató TV3 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer-Ingelheim : Renal disease
	2022 Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
	2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee
Borger Michael A	2021 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Borger Michael A	<p>2022 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
	<p>2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p>
Buccheri Sergio	<p>2021 Nothing to be declared</p>
	<p>2022 Nothing to be declared</p>
	<p>2023 Nothing to be declared</p>
Ibanez Borja	<p>2021 Nothing to be declared</p>
	<p>2022 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
	<p>2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Proctorship</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p>
Kober Lars	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kober Lars	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Novo-Nordisk : Chronic Heart Failure</p>
Koskinas Konstantinos	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Cardiology</p>
	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p>
Mcevoy John William	<p>2021</p> <p>Nothing to be declared</p>
	<p>2022</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Mcevoy John William	2023	Nothing to be declared
Mihaylova Borislava	2021	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : Anacetrapib National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy Barts Charity : Digital pathology National Institute for Health Research : Various clinical studies including economic evaluations</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Merck Sharp & Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>
	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>
Mindham Richard	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincls.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. NiCE (National Institute for Health & Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. http://passpaces.co.uk/. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p>2023</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I support the British charity CardiomyopathyUK, https://www.cardiomyopathy.org.uk/. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, https://pumpingmarvellous.org/. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, https://bureaucracyincts.eu/. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase & sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p>2021</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial fibrillation</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Pfizer : Atrial Fibrillation (AF),</p> <hr/> <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Nielsen Jens Cosedis	2021	Nothing to be declared
	2022	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
	2023	Nothing to be declared
Pasquet Agnes A	2021	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. member of the Belgian Society of Cardiology</p>
	2022	<p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
	2023	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Philips : echography, contribution and support</p>
Prescott Eva	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Prescott Eva	2022	Nothing to be declared
	2023	Nothing to be declared
Rakisheva Amina	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer : Atrial Fibrillation Novartis : Heart Failure
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
	2023	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
Rocca Bianca	2021	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : anticoagulant (rivaroxaban)
	2022	Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Aboca SRL : Other Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Bayer AG : study on low dose rivaroxaban, Chief investigator

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Rocca Bianca	2023	<p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Rossello Francisco Javier	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Vaartjes Ilonca	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Vrints Christiaan J M	2021	Nothing to be declared
	2022	Nothing to be declared
	2023	Nothing to be declared
Witkowski Adam	2021	<p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Witkowski Adam	<p>2022</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
	<p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy</p>
Zeppenfeld Katja	<p>2021</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : Research electrophysiology</p>
	<p>2022</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). Biosense Webster : investigator initiated research, PI</p>
	<p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>